Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Miriam Pikkemaat und 9 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Angiopathies, Apolipoproteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
Whether apolipoproteins (apolipoprotein A1, apolipoprotein B, apolipoprotein B/apolipoprotein A1 [ApoB/ApoA1] ratio) or very‐low‐density lipoprotein (VLDL) cholesterol are better risk predictors than established lipid risk markers, and whether there are sex differences, is uncertain, both in general populations and in patients with diabetes. The aim of this study was to assess the association between established risk markers, apolipoproteins and the risk of macro‐ and microvascular disease and death in a large study of women and men with diabetes and to assess the potential sex differences in the associations. Materials and Methods Established lipid risk markers were studied in 11 140 individuals with type 2 diabetes from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified‐Release Controlled Evaluation (ADVANCE) trial, and apolipoproteins (A1, B, ApoB/ApoA1 ratio) and VLDL cholesterol from nuclear magnetic resonance (NMR) lipid analyses in biobanked samples from 3586 individuals included in the ADVANCE case‐cohort study (ADVANCE CC). Primary outcomes were major macro‐ and microvascular events and death. Cox proportional hazards models adjusted for confounders were used to quantify the associations (hazard ratio [HR] and 95% confidence intervals [CIs]) between established lipid risk markers and apolipoproteins with study outcomes. To address potential effect modification by sex, we investigated the association between the lipid risk markers and outcomes in subgroup analyses by sex.
Results
There was a lower risk of macrovascular complications for high‐density lipoprotein (HDL) cholesterol (HR [95%CI] 0.88 [0.82–0.95]), a higher risk for total cholesterol (1.10 [1.04–1.17]), low‐density lipoprotein (LDL) cholesterol (1.15 [1.08–1.22]), non‐HDL cholesterol (1.13 [1.07–1.20]) and the total cholesterol/HDL ratio (1.20 [1.14–1.27]) but no significant associations with triglycerides from ADVANCE. There was a higher risk of macrovascular complications for the ApoB/ApoA1 ratio (1.13 [1.03–1.24]) from the ADVANCE CC. Only the ApoB/ApoA1 ratio (1.19 [1.06–1.34]), but none of the established lipid risk markers, was associated with a higher risk of microvascular complications. There were no statistically significant sex differences for any of the established lipid risk markers or apolipoproteins with any outcome. Using C‐statistics and net reclassification improvement (NRI) did not detect significant improvement in predicting all outcomes by adding lipids or apolipoproteins to the models with confounding factors only. Conclusions/Interpretation All established lipid risk markers, except triglycerides, were predictors of macrovascular complications, but not microvascular complications, in patients with type 2 diabetes. The ApoB/ApoA1 ratio was associated with major macro‐ and microvascular complications, but there was no evidence that apolipoproteins are better than established lipid risk markers in predicting cardiovascular complications in patients with type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.
- Center for Primary Health Care Research, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden.
- University Clinic Primary Care Skåne, Malmö, Sweden.
- The George Institute for Global Health, School of Public Health, Imperial College London, London, UK.
- Department of Health, Medicine and Caring Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
- Department of Anatomy and Physiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
ORCID-Profile: Miriam Pikkemaat, Mark Woodward, Peder Af Geijerstam, Stephen Harrap, Giuseppe Mancia, Neil Poulter, John Chalmers, Katie Harris
Förderung
- National Health and Medical Research Council
Zitieren
APA
Pikkemaat, M., Woodward, M., Af Geijerstam, P., Harrap, S., Hamet, P., Mancia, G., Marre, M., Poulter, N., Chalmers, J., & Harris, K. (2024). Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15935
Vancouver
Pikkemaat M, Woodward M, Af Geijerstam P, Harrap S, Hamet P, Mancia G, et al. Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15935
BibTeX
@article{Pikkemaat2024,
author = {Pikkemaat, Miriam and Woodward, Mark and Af Geijerstam, Peder and Harrap, Stephen and Hamet, Pavel and Mancia, Giuseppe and Marre, Michel and Poulter, Neil and Chalmers, John and Harris, Katie},
title = {Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15935}
}
EUVIMED